Grail shares rise 33% after FDA documents hint at favorable review of Galleri cancer test

Shares in Grail rose 33% on Monday after the FDA posted briefing documents ahead of a Wednesday advisory committee meeting on Galleri, its blood test for early detection of many cancers. The documents suggest the agency may view the test favorably. FDA approval would help secure Medicare and insurance reimbursement; the test is already sold as a lab diagnostic.